Supply High Purity Bivalirudin Tfa, Bivalirudin Trifluoroacetate CAS 128270-70-1

Appearence: White Powder
Supply Ability: 500000kg/Year
Certificate: GMP
Packing: Plastic Tube
Shelf Life: 2years
Storage Way: Dry and Cool Place
Trademark: FILTER
Transport Package: Plastic Tube / Vial
Specification: 2mg/vial, 10vials/box
Origin: Shanghai
HS Code: 3003901000
Appearence: White Powder
Supply Ability: 500000kg/Year
Certificate: GMP
Packing: Plastic Tube
Shelf Life: 2years
Storage Way: Dry and Cool Place
Trademark: FILTER
Transport Package: Plastic Tube / Vial
Specification: 2mg/vial, 10vials/box
Origin: Shanghai
HS Code: 3003901000
Supply High Purity Bivalirudin TFA, Bivalirudin Trifluoroacetate CAS 128270-70-1

Production Information:
Bivalirudin
  is a specific and reversible direct thrombin inhibitor (DTI).

Chemically, it is a synthetic congener of the naturally occurring drug hirudin 

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor ofthrombin. It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation.Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.
 

Application: 
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI. Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Supply High Purity Bivalirudin Tfa, Bivalirudin Trifluoroacetate CAS 128270-70-1
 

Contact us:
Maria
 
 
 
 
Supply High Purity Bivalirudin TFA, Bivalirudin Trifluoroacetate CAS 128270-70-1

Production Information:
Bivalirudin
  is a specific and reversible direct thrombin inhibitor (DTI).

Chemically, it is a synthetic congener of the naturally occurring drug hirudin 

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor ofthrombin. It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation.Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.
 

Application: 
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI. Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Supply High Purity Bivalirudin Tfa, Bivalirudin Trifluoroacetate CAS 128270-70-1
 

Contact us:
Maria